Tamoxifen therapy for patients with breast cancer – Authors' reply-Reference-Cited by-同舟云学术

Tamoxifen therapy for patients with breast cancer – Authors' reply

Published:2013-06 Issue:9883 Volume:381 Page:2078-2079
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Davies Christina,Gray Richard,Pan Hongchao,Peto Richard

Publisher

Elsevier BV

Subject

General Medicine

Reference5 articles.

1. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials;Lancet,2011

2. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen-receptor positive breast cancer: ATLAS, a randomised trial;Davies;Lancet,2013

3. Five years of tamoxifen or more?;Peto;J Natl Cancer Inst,1996

4. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer;Gray;J Clin Oncol,2013

5. Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care;Peto;Br J Cancer,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer;Therapeutic Advances in Medical Oncology;2023-01

2. Solving current dilemmas in the adjuvant endocrine treatment of pre- and perimenopausal women with an estrogen receptor positive breast cancer;European Journal of Gynaecological Oncology;2021

3. Adjuvante endokrine Therapie beim Mammakarzinom: Was ist der aktuelle Stand?;Der Gynäkologe;2019-04-23

4. The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer;Current Treatment Options in Oncology;2015-06-02